Insurance Barriers Limit Access to Injectable PrEP in St. Louis

A recent study found that insurance issues prevented over 40 percent of patients at a St. Louis clinic from receiving treatment.

Updated on Oct. 23, 2026 in Diabetes

Insurance Barriers Limit Access to Injectable PrEP in St. Louis

Live Poll

Should insurance companies simplify their approval processes for preventative medical treatments?

A retrospective study of patients prescribed long-acting injectable PrEP at a St. Louis clinic reveals that 41.2 percent failed to receive the medication. Researchers linked the primary obstacles to significant pharmacy benefit gaps and prior authorization denials.

Why it matters

These insurance hurdles prevent patients from accessing preventative care, which can lead to increased risks of HIV seroconversion. Addressing these systemic barriers is essential for ensuring that patients can utilize effective, long-acting prevention methods.

A study found that 54.3 percent of non-recipients lacked pharmacy benefits, while 41.4 percent faced prior authorization denials. For those who did receive the medication, the median time from prescription to injection was 12 days.

The players

UC Davis Health

This academic health system participated in the survey to improve resident knowledge of long-acting PrEP.

UChicago Medicine

This institution contributed to the educational curriculum study for internal medicine residents.

The details

The study tracked 170 patients between February 2022 and July 2026, noting that 70 individuals never received their prescribed injection. Researchers also found that internal medicine residents at other institutions showed improved prescribing confidence after completing a specialized curriculum.

The study period for patients with at least one prescription ran from February 1, 2022 to July 7, 2026.
The cutoff for the detailed patient analysis group occurred in March 2026.
Research findings were presented in October 2026 at the IDWeek 2026 conference.

The Big Picture

This study follows research presented at IDWeek 2026. It marks a contribution to the broader body of clinical research presented at the conference regarding preventative health implementation.

Patients may face significant wait times or administrative denials when seeking injectable preventative treatments. Individuals should verify their specific pharmacy benefits and work closely with providers to navigate the prior authorization process.

The takeaway

Insurance denials for preventative medications create critical gaps in care that can negatively impact patient health outcomes. Patients should proactively contact their insurance providers to confirm coverage and reduce the risk of treatment delays.